NCT03530995View on ClinicalTrials.gov

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

February 8, 2019

Study Completion Date

February 8, 2019

Conditions
Drug-drug InteractionAutoimmune DiseasesFibrotic Disease
Interventions
DRUG

Belumosudil

Development candidate

DRUG

Itraconazole

Perpetrator drug

DRUG

Rabeprazole

Perpetrator drug

DRUG

Rifampicin

Perpetrator drug

DRUG

Omeprazole

Perpetrator drug

Trial Locations (1)

NG11 6JS

Quotient Sciences Ltd, Ruddington

All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Kadmon Corporation, LLC

INDUSTRY

NCT03530995 - Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers | Biotech Hunter | Biotech Hunter